| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. | Director | Common Stock | 2.2M | $3.85M | $1.75 | Sep 29, 2025 | Indirect |
| SAB Biotherapeutics, Inc. | Director | Series B Convertible Preferred Stock | 211K | Sep 29, 2025 | Indirect | ||
| SAB Biotherapeutics, Inc. | Director | Warrants (right to buy) | 114K | Jul 22, 2025 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| SABS | SAB Biotherapeutics, Inc. | Sep 29, 2025 | 2 | $3.05M | 4 | Oct 1, 2025 | Director |
| SABS | SAB Biotherapeutics, Inc. | Jul 22, 2025 | 3 | $0 | 4 | Jul 24, 2025 | Director |
| SABS | SAB Biotherapeutics, Inc. | Nov 24, 2023 | 3 | -$2.89M | 4 | Nov 28, 2023 | Director |
| SABS | SAB Biotherapeutics, Inc. | Nov 10, 2023 | 1 | $13.3M | 4/A | Nov 15, 2023 | Director |
| SABS | SAB Biotherapeutics, Inc. | Oct 23, 2023 | 2 | $16.3M | 4 | Oct 24, 2023 | Director |
| SABS | SAB Biotherapeutics, Inc. | Oct 2, 2023 | 0 | $0 | 3 | Oct 10, 2023 | Director |